Bioscience & Pharmaceutical

With many therapies now in the clinical study phase, Prelude Therapeutics has received state approval to receive $2.6 million from previous grant awards early to aid the companies’ expansion efforts

The Alliance for Chemical Distribution Executive Director Eric Byer visited Delaware and talked about trade, workforce issues and regulation.

With Prelude's finance officer out, the rising biopharmaceutical company is now searching for a new chief financial officer.

Incyte has signed a deal with China Medical System Holdings Limited on povorcitinib. Terms of the deal were not disclosed.

Delaware Business Times Editor Katie Tabeling looks at the challenges many bioscience start-up companies face that seek to push boundaries in medical and scientific research.

The top life science conference “Delaware’s DNA” will be back this May, and in its second year it will focus on how deep the roots of Delaware’s bioscience industry goes.

Padraig McDonnell has been named as the next CEO of Agilent, as its current leader Mike McMullen prepares to retire.

To continue to develop cutting-edge treatments to cure cancer and other serious issues, Delaware's bioscience companies look for the best team possible and those who believe in their mission.

After collaborating with MorphoSys on a developing cancer treatment Monjuvi, Incyte has bought full rights to develop the immunotherapy and bring it to market.

Prelude Therapeutics cut the ribbon on its new headquarters on Friday morning, signaling the next chapter in the company's growth.